Precigen (STU:I5X) EPS (Basic): €-1.01 (TTM As of Mar. 2026)

What is Precigen EPS (Basic)?

Precigen STU:I5X +2.54% 58 EPS (Basic) is €-1.01 as of Mar. 2026. GuruFocus rates STU:I5X with a GF Score™ of 58/100 and a GF Value™ of €5.40 (Modestly Undervalued). The stock has 10 warning signs investors should review.

Precigen's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was €-0.02. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was €-1.01.

Precigen's EPS (Diluted) for the three months ended in Mar. 2026 was €-0.02. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-1.01.

Precigen's EPS without NRI for the three months ended in Mar. 2026 was €-0.02. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -0.70.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Precigen (STU:I5X) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Precigen EPS (Basic) Related Terms

Precigen EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Precigen's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Precigen EPS (Basic) Chart

Precigen Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EPS (Basic)

Get a 7-Day Free Trial

-0.42

0.13

-0.36

-0.45

-1.17

Precigen Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EPS (Basic)	Get a 7-Day Free Trial															-0.17	-0.08	-0.90	-0.01	-0.02

58GF Score

Precigen Inc STU:I5X

EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Precigen EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Precigen's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-214.048	-	152.866)	/	312.981
	=	-1.17

Precigen's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-6.859	-	0)	/	354.291
	=	-0.02

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.01

Frequently Asked Questions Learn more about EPS (Basic) →

What does a EPS (Basic) of €-1.01 mean?

Precigen (STU:I5X) has a EPS (Basic) of €-1.01 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Precigen and its competitors.

Is Precigen's EPS (Basic) too high?

Precigen's current EPS (Basic) is €-1.01. Overall, Precigen has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Precigen's EPS (Basic) compare to DMRA and INBX?

Precigen's EPS (Basic) of €-1.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EPS (Basic) for a Biotechnology company?

A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EPS (Basic) mean?

A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Precigen and its competitors. Precigen's current EPS (Basic) is €-1.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Precigen stock overvalued right now?

Based on GuruFocus' analysis, Precigen (STU:I5X) is currently considered Modestly Undervalued. The stock's GF Value™ is €5.40, compared to a current price of €4.84 — trading 10.4% below its estimated fair value. The current EPS (Basic) is €-1.01. Precigen's overall GF Score™ is 58/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EPS (Basic) calculated?

EPS (Basic) is calculated from a company's financial statements. For Precigen (STU:I5X), the current EPS (Basic) is €-1.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Precigen (STU:I5X) Overvalued in 2026?

Based on GuruFocus' analysis, Precigen stock appears to be undervalued. The current stock price of €4.84 is trading 10.4% below its estimated GF Value™ of €5.40. GuruFocus considers Precigen to be Modestly Undervalued.

Key valuation signals for STU:I5X:

EPS (Basic): €-1.01
GF Value™: €5.40 vs. price of €4.84 (10.4% below fair value)
GF Score™: 58/100 with 10 warning signs

No single metric tells the full story. See the STU:I5X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Precigen Business Description

Industry Healthcare Biotechnology

Comparable Companies DMRA INBX IMTX INVA MBX ARDX VIR ANAB MAZE FTRE VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges PGEN:USA

Address 20374 Seneca Meadows Parkway, Germantown, MD, USA, 20876

Website http://www.precigen.com

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

58GF Score

Get the complete analysis for STU:I5X

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.84

Price

€5.40

GF Value

View STU:I5X Analysis

See EPS (Basic) data for all stocks →